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Abstract. 
 
Fibronectin’s RGD-mediated binding to the 
 
a
 
5
 
b
 
1 integrin is dramatically enhanced by a synergy 
site within ﬁbronectin III domain 9 (FN9). Guided by 
the crystal structure of the cell-binding domain, we se-
lected amino acids in FN9 that project in the same di-
rection as the RGD, presumably toward the integrin, 
and mutated them to alanine. R1379 in the peptide
PHSRN, and the nearby R1374 have been shown previ-
ously to be important for 
 
a
 
5
 
b
 
1-mediated adhesion 
 
(Aota, S., M. Nomizu, and K.M. Yamada. 1994. 
 
J. Biol. 
Chem.
 
 269:24756–24761). Our more extensive set of 
mutants showed that R1379 is the key residue in the 
synergistic effect, but other residues contribute sub-
stantially. R1374A decreased adhesion slightly by itself, 
but the double mutant R1374A-R1379A was signiﬁ-
 
cantly less adhesive than R1379A alone. Single
 
 
 
muta-
tions of R1369A, R1371A, T1385A, and N1386A
 
 
 
had 
negligible effects on cell adhesion, but combining these 
substitutions either with R1379A or each other gave a 
more dramatic reduction of cell adhesion. The triple 
mutant R1374A/P1376A/R1379A had no detectable 
adhesion activity. We conclude that, in addition to the R 
of the PHRSN peptide, other residues on the same face 
of FN9 are required for the full synergistic effect. The 
integrin-binding synergy site is a much more extensive 
surface than the small linear peptide sequence.
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Introduction
 
One of the best characterized integrin–ligand interactions
is 
 
a
 
5
 
b
 
1 binding to fibronectin (FN).
 
1
 
 The RGD sequence
in the FN III domain 10 (FN10) is the key binding site for
 
a
 
5
 
b
 
1 (Pierschbacher and Ruoslahti, 1984), but it also has
been found that the FN III domain 9 (FN9) contributes
importantly to adhesion. Although FN9 has no adhesive
activity by itself, it causes an 
 
z
 
100-fold increase in cell ad-
hesion to FN via 
 
a
 
5
 
b
 
1. Thus, the adhesive region in FN9
has been called the synergy site (Obara et al., 1988; Kimi-
zuka et al., 1991; Aota et al., 1994).
The synergy site in FN9 has been mapped using a series
of chimeric FN9-10 fragments in which regions of FN9
were replaced with the equivalent residues from FN8
(Aota et al., 1994). These homology scanning mutants re-
vealed the importance of P1376-N1380 (PHSRN) to the
synergy effect, and site-directed mutagenesis showed that
R1379 was a key residue in the synergy site. An R1374/
R1379 double mutant also had a dramatic effect on syn-
ergy, and the authors concluded that R1374 and PHSRN
were the major components of the synergy site (Aota et
al., 1994). The integrin 
 
a
 
IIb
 
b
 
3 apparently uses a similar
synergy site, since the peptide DRVPHSRNSIT inhibited
binding of FN to this integrin (Bowditch et al., 1994).
The requirement of the synergy site for maximum adhe-
sion to the FN via 
 
a
 
5
 
b
 
1 is not absolute, however, since
fully activated 
 
a
 
5
 
b
 
1 binds equally well to fibronectin frag-
ments in which the classic PHSRN synergy site was highly
mutated (Danen et al., 1995). This abrogation of the need
for the synergy site by integrin activation also extends to
matrix assembly. FN with a synergy mutation was shown
to be poorly incorporated into matrix, yet exogenous acti-
vation of integrins stimulated incorporation of the mutant
FN into the extracellular matrix (Sechler et al., 1997). The
synergy site has been shown to have a physiological role in
 
Xenopus
 
 development, as an antibody against it blocked
gastrulation (Ramos and DeSimone, 1996).
The three-dimensional structure of the FN III domains
7–10 (FN7–10) revealed that the PHSRN site and the
RGD loop are 
 
z
 
35 Å apart but are on the same side of the
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FN molecule (Leahy et al., 1996), suggesting that both sites
can contact the same integrin. The orientation and position-
ing of the FN III domains with respect to each other would
be critical if the integrin binding includes both sites. Inser-
tion of short (2–6 amino acid) linkers between domains
9 and 10 significantly decreased cell adhesion (Grant et al.,
1997). The introduction of the linkers could result in re-
duced adhesion by altering the distance between the RGD
and the synergy site, by allowing more random rotation of
the two domains, or by a combination of these effects.
Since the PHSRN and RGD sites are separated by 35 Å,
we considered the possibility that amino acids in this inter-
vening surface, other than PHSRN, might contribute to
the synergy site. Using the three-dimensional structure of
FN7–10 as a guide, we identified candidate amino acids
based on the following two criteria: (1) that they face in
the same direction as RGD and PHSRN (toward the inte-
grin); and (2) that they project from the protein surface.
We made a series of single site-directed mutants, further
combined them in pairs and triplets, and tested each of the
recombinant proteins for cell adhesion.
We have found that R1379 of the PHSRN site is a major
component of the synergy site, but mutating several other
residues on the surface of FN9 also significantly reduced
the synergy effect. Some residues had no observable effect
when mutated singly, yet they reduced cell adhesiveness
when combined with other mutations. In all cases, combin-
ing mutations augmented the effects of deleterious single
mutations, particularly when the combination included
R1379A.
 
Materials and Methods
 
Cells
 
K-562 cells (ATCC number CCL-243) and TS2/16 hybridomas were ob-
tained from A. Garcia (Georgia Institute of Technology, Atlanta, GA).
K-562 cells were cultured in DME supplemented with 10% calf serum and
penicillin/streptomycin. TS2/16 hybridomas were maintained in DME
supplemented with 10% FBS and penicillin/streptomycin. K-562 cells
were activated for adhesion assays by incubating with the TS2/16 culture
supernatant for 30 min at 4
 
8
 
C (Danen et al., 1995; Garcia et al., 1999).
 
Site-directed Mutagenesis, Expression, and Purification
 
A plasmid containing FN III domains 7–10 (FN7–10) in the pET11b vec-
tor was constructed previously (Aukhil et al., 1993; Leahy et al., 1996).
This plasmid was used as a template for site-directed mutagenesis using
the Quick-Change mutagenesis kit (Stratagene), as directed by the manu-
facturer. In brief, complementary primers containing the desired mutation
were annealed to the template plasmid and the 
 
Pfu
 
 polymerase was used
to replicate the template, incorporating the mutant primers. Digestion
with DpnI was used to fragment the template DNA before bacterial trans-
formation with the PCR mix. After verification of the mutant plasmid se-
quence, proteins were expressed and purified essentially as described pre-
viously (Leahy et al., 1996), except that chromatography on Mono S was
replaced by crystallization in 0.02 M sodium formate, pH 4.35. The protein
from the Mono Q was dialyzed for 1–8 h against the sodium formate, and
the crystalline precipitate was collected by centrifugation. This precipita-
tion gives the same high purity as chromatography on Mono S without the
substantial losses that we realize during Mono S chromatography.
 
Cell Adhesion Assay
 
Cell adhesion to the fibronectin fragments was quantitated using the cen-
trifugal force assay of McClay and Hertzler (1999), with a few significant
modifications. In brief, the wells of a 96-well plate were coated with 20 
 
m
 
g/
ml (high FN) or 0.8 
 
m
 
g/ml (low FN) solutions (in PBS) of the proteins to
be tested and blocked with 10 mg/ml BSA in PBS. Activated K-562 cells
were labeled with rhodamine B isothiocyanate (Sigma Chemical Co.), and
10
 
4
 
 cells were plated into each well of the 96-well plate. The wells were
filled with medium and sealed with transparent tape (3M book tape). A
swinging bucket centrifuge fitted with microplate carriers was used to sub-
ject the plate to a force of 50
 
3
 
 G for 5 min at 4
 
8
 
C, gently forcing the cells
into contact with the substrate. The plate was immediately inverted and
the same force was applied for 5 min at 4
 
8
 
C to dislodge the cells that did
not adhere to the substrate. The inverted plate was examined by fluores-
cence microscopy using either a Nikon Axiophot or Axioplan microscope
equipped with a Star 1 digital camera (Photometrics Inc.). A digital image
of the central 44% of each well was captured and examined using the pub-
lic domain NIH Image program (developed at the National Institutes of
Health and available on the internet at http://rsb.info.nih.gov/nih-image/).
Thresholding and particle analysis were used to count the number of
bound cells in the imaged area of each well. The number of cells bound to
a set of four wells (see below) was normalized to the number of cells
bound to a set of four FN7–10-coated wells on the same plate.
We used tissue culture–treated polystyrene 96-well plates (Costar
#3596; Costar Corp.) for our assays since we could not get reproducibly
uniform protein coating of the PVC plates that were used in the original
assay. On the PVC plates, we frequently observed a bull’s-eye effect: cells
bound preferentially around the edge of the well and to a spot in the cen-
ter, leaving a cell-free annulus between the central spot and the edge. Oc-
casionally, we also noticed a reverse bull’s-eye in our BSA-coated control
wells: a cell-covered annulus between a cell-free central spot and the cell-
free well edge. Both effects were exacerbated by a low protein concentra-
tion, and this unpredictably uneven cell distribution prevented any sort of
quantitative analysis. On the polystyrene plates, we rarely saw this sort of
annular cell distribution. Thanks to the rimmed well design of the polysty-
rene plates, we were able to plate cells into all 96 wells.
We noticed that the wells on the outside of the plate tended to have
cells accumulate toward the outside edge, with a consequent depletion to-
ward the inside edge. This effect can be explained by the radial distribu-
tion of G forces. In the center of the plate, the G force is precisely perpen-
dicular to the surface of the well but, at the edges, it acquires a small
component parallel to the surface and toward the outside of the plate.
This is a small effect, but to eliminate the associated error, we arranged
the wells so that each substrate was coated on a set of four wells, on one
side of the 8-well row, and we averaged these four wells to give a set aver-
age. All data presented here represent a further averaging of triplicate or
quadruplicate set averages with the exception of the data from the
R1371A/R1379A double mutant that is the average of two set averages.
The SEM was calculated for this average of the set averages. For each ex-
periment, the number of cells bound to a set of FN7–10-coated wells was
compared with the number of cells bound to a set of wells that were not
blocked with BSA (cells bound strongly to this uncoated plastic). The
number of cells bound to the high and low FN concentrations was 100 
 
6
 
2% and 71 
 
6
 
 4% of the number of cells bound to the uncoated plastic.
 
Competitive Inhibition Assay
 
Our competitive inhibition assay was a slight modification of the cell ad-
hesion assay described above. For this assay, each of the wells of a polysty-
rene 96-well plate was coated with 50 
 
m
 
l of 20 
 
m
 
g/ml FN7–10 in PBS, and
then blocked with 10 mg/ml BSA in PBS. The soluble protein to be tested
as a competitor was added to the well immediately before the activated
K-562 cells. After the centrifugation steps, the wells were imaged and ana-
lyzed as above.
 
Gradient Sedimentation Analysis
 
Wild-type FN7–10, FN7–10 mutants, and standard proteins were sedi-
mented through 5-ml linear gradients of 15–40% glycerol in 0.2 M ammo-
nium bicarbonate (Aukhil et al., 1993). Fractions of these gradients were
analyzed by SDS-PAGE.
 
Results
 
Cell Adhesion Assays
 
We used the centrifugation assay of McClay and Hertzler
(1999) to measure adhesion because it gives a reproduc- 
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ible quantitative measure of receptor–ligand interactions.
The forces experienced by the cells during the centrifuga-
tion assay are limited to those applied by the centrifuge,
unlike the uncharacterized fluid shear forces generated by
pipetting and washing during the more traditional assay.
In addition, most cell adhesion assays include an incu-
bation at 37
 
8
 
C, usually for 30–60 min, during which the
cells spread on the adhesive substrate. The cytoskeletal
coupling that occurs during spreading makes the cells
more rigid, therefore, more resistant to detachment, even
though the number and strength of ligand–receptor inter-
actions may be unchanged. To avoid the effects of cell
spreading, we did the adhesion assay at 4
 
8
 
C and completed
the assay in 15 min.
Aota et al. (1994) have demonstrated by site-directed
mutagenesis that R1379, in the PHSRN sequence, was a
critical component of the synergy site, and demonstrated
that the nearby R1374 was also important. Based on the
three-dimensional atomic structure (Leahy et al., 1996),
we selected these two and five additional amino acids in
FN9 as likely candidates to contribute to integrin binding,
based on a geometry projecting them toward the integrin
(Fig. 1). Each of these residues is highly conserved in all
seven species for which FN has been sequenced (Fig. 1),
and we found all of them to be fully exposed to solvent be-
yond the beta carbon. All of our mutations replaced the
side chain with the single methyl group of alanine. We be-
gan by replacing R1374 and R1379 with A, both singly and
in tandem. These mutations confirmed that R1379 makes
a significant contribution to the synergy effect, as R1379A
reduced cell adhesion to 
 
z
 
75% of that to wild-type FN7–
10 (Fig. 2). R1374 makes a smaller contribution to this ef-
fect, as R1374A reduced adhesion to 
 
z
 
85% of the wild
type (Fig. 2). We also confirmed the observation of Aota
et al. (1994) that the effects of R1374A and R1379A were
additive. Adhesion to the double mutant was 
 
z
 
55% of ad-
hesion to wild-type FN7–10 (Fig. 2).
Although the data of Aota et al. (1994) suggested that
only R1379 of the PHRSN sequence was critical for the
synergistic effect, all of their mutants contained a proline
at either position 1376 or 1377. To test the importance of
proline in the PHSRN site, we made the triple mutant
R1374A/P1376A/R1379A. Cell adhesion to this mutant
protein was essentially destroyed (Fig. 2). For a control,
we constructed a protein in which the RGD sequence
was deleted (we deleted the four amino acids RGDS, as
the three-dimensional structure showed that this deletion
would cause minimal distortion of the domain). We also
tested FN10, a single domain protein that lacks the syn-
ergy domain. Both 
 
D
 
RGDS and FN10 gave negligible ad-
hesion (Fig. 2).
The atomic structure shows T1385 and N1386 to be the
most prominent amino acids protruding from the surface
of FN9 between the PHSRN loop and the RGD loop of
FN10 (Fig. 1). Surprisingly, neither T1385A nor N1386A
had a significant effect on cell adhesion under the assay
conditions we were using, specifically to wells coated at 20
 
m
 
g/ml (Fig. 3, high FN). Therefore, we constructed the
double mutant, T1385A/N1386A, and found that this mu-
tant reduced adhesion slightly, to 
 
z
 
80% of the wild type
(Fig. 3, high FN).
In these initial assays, the wells were coated at 20 
 
m
 
g/ml
protein (high concentration). We found that a lower con-
centration of the coating protein gave a much more sensi-
tive indication of adhesion defects. Fig. 3 also shows the
assay with wells coated with 0.8 
 
m
 
g/ml of recombinant
protein (low concentration). Although cell adhesion to
T1385A or N1386A was indistinguishable from wild type
at the high coating concentration, adhesion to T1385A or
N1386A was 
 
z
 
85 or 80% that of the wild-type FN7–10, re-
spectively, at the low concentration (Fig. 3, low FN). Ad-
Figure 1. Two views of the three-dimensional structure of FN9-
10 (PDB ID: 1fnf; Leahy et al., 1996) and a linear representation
of the relevant regions. The RGDS segment is in red, and the two
residues with the next strongest effect on adhesion (R1445 and
R1379) are in magenta. The remainder of the PHSRN site is
shown in light blue (mutation of these residues had little effect on
adhesion activity (Aota et al., 1994)). The residues shown in yel-
low contribute to adhesion, but the effects of these mutations are
most obvious when combined with the mutation R1379. The
C-C9 loop (NSP), which does not contribute to adhesion, is col-
ored green. A linear representation of the relevant sequences is
shown below with residue coloring corresponding to that shown
above. The amino acid sequence of FN is shown for the seven
species from which it has been cloned. 
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hesion to the low concentration of the T1385A/N1386A
double mutant was reduced to 
 
z
 
30% of binding to the
wild type (Fig. 3, low FN), and adhesion to the low concen-
tration of R1379A was 
 
z
 
20% that of wild type (data not
shown). We also tested adhesion to an R1379A/T1385A/
N1386A triple mutant; this showed 30 and 5% of adhesion
to wild type at the high and low concentrations (Fig. 3).
Two other surface-exposed residues on the PHSRN face
of FN9 were tested, R1369 and R1371. R1369A had no ef-
fect on cell adhesion at either high or low protein concen-
tration (Fig. 4). R1371A showed no effect at a high con-
centration, but at a low concentration adhesion was
reduced to 65% that of the wild type (Fig. 4). When either
R1369A or R1371A was combined with R1379A, adhe-
 
sion was dramatically reduced. Adhesion to either of these
double mutants was 40% that of the wild type at a high
coating concentration, and was completely eliminated (5%
of wild type) at a low concentration (Fig. 4). Adhesion
to these double mutants was comparable to adhesion
to R1374A/R1379A, yet, unlike R1374A, R1369A and
R1371A had little or no effect by themselves (compare
Fig. 2 with Fig. 4, high).
In addition to the synergy residues in FN9, we tested
two mutants in FN10. The bulky and charged side chain of
R1445, which is distant from the RGD in the linear se-
quence, but immediately behind the RGD loop in the
three-dimensional structure, was replaced by A. This mu-
tation had a dramatic effect on cell adhesion, giving just
60% of binding to the wild type at a high concentration
and 
 
z
 
15% of wild-type binding at a low concentration
(Fig. 3). We also tested the role of the loop connecting the
C-C
 
9
 
 strands by replacing all three amino acids, NSP, with
A. This mutation had no effect on adhesion, suggesting
that the C-C
 
9
 
 loop does not make an important contact
with the integrin (data not shown).
 
Competitive Inhibition Assays
 
Since competitive inhibition has been used as a sensitive
indicator of the cell adhesive activity of mutant fibronectin
fragments (Aota et al., 1994), we tested several of our re-
combinant proteins for their ability to block cell adhesion
to wild-type FN7–10. For each protein, we tested four dif-
ferent concentrations of soluble protein, from 0.037 to 37
 
m
 
M in 10-fold dilutions (Fig. 5). We found that T1385A
and N1386A inhibited cell adhesion nearly as well as wild-
type FN7–10, although the small decrease in competition
for the mutants was consistent and probably significant.
The competitive activity of R1379A, on the other hand,
was 
 
z
 
100-fold less than wild-type FN7–10. FN10 was
equally ineffective in competition. These results confirm
that replacing R1379 with A has a devastating effect on
cell adhesion, while replacing T1385 or N1386 with A has
only a small effect. Since R1379A was essentially inactive
in the competition assay, we did not expect to see any en-
hancement of added mutations, and did not test the dou-
ble mutants in this assay.
Figure 2. Cell adhesion to proteins with mutations in or adjacent
to the PHRSN sequence. DRGDS and FN10 were included as
controls to indicate adhesion in the absence of RGD or FN9. The
average number of cells bound to each protein is given as a per-
centage of the number of cells attached to wild-type FN7–10.
Note that in this experiment, the wells were coated with 20 mg/ml
protein, which is the high concentration in later experiments.
Figure 3. Cell adhesion defects of T1385A and N1386A mutants.
We tested cell adhesion to plates coated with two concentrations
of wild-type and mutant FN7–10: 20 mg/ml (high FN) or 0.8 mg/ml
(low FN). Adhesion to each mutant protein was normalized to the
wild type at each coating concentration; adhesion to 0.8 mg/ml
wild-type FN7–10 was z70% of adhesion to 20 mg/ml. The low
concentration of FN gave a more sensitive indication of adhesion
defects.
Figure 4. Arginine residues 1369 and 1371 were examined for
their effect on adhesion. Plates were coated with 20 mg/ml (high
FN) or 0.8 mg/ml (low FN) of the indicated mutant FN7–10. 
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Integrity of the Mutant Proteins
 
To interpret site-directed mutagenesis, it is important to
know that the mutation does not simply disrupt the folding
of the domain. All of the amino acids that we selected here
are seen in the crystal structure to be projecting from the
domain surface, and they have minimal buried surface be-
yond the beta
 
 
 
carbon, so we did not expect any of the mu-
tants to affect folding. All mutant proteins were recovered
as soluble from the bacterial expression, and were mono-
meric as determined by sedimentation (see below). We
have an important additional criterion for proper folding,
in that our final purification step is the formation of a crys-
talline precipitate in sodium formate, pH 3.35. All of our
mutant proteins crystallized identically to the wild-type
protein, which is strong evidence that they have an identi-
cal three-dimensional structure.
To confirm that the mutant proteins were indeed mono-
meric, several were further tested by gradient sedimenta-
tion. Double and triple mutant proteins were chosen that
included each of the seven mutations. The wild-type and
all mutant proteins sedimented identically in fraction 8.5,
about 3.5 S as determined by comparison to standards
(Fig. 6). Even R1374A/P1376A/R1379A, where the pro-
line mutation might have altered the peptide conforma-
tion, showed no alteration in sedimentation or in the crys-
tallization step of purification.
In contrast to these surface amino acids, we have also
made mutations of the central tryptophan residues in FN9
and FN10. Here, we made the conservative change W
 
®
 
F,
but were still concerned that this might disrupt the struc-
ture, since the tryptophan is completely buried in the pro-
tein core, and almost totally conserved in FN-III domains.
The W
 
®
 
F mutation in FN10 gave soluble protein that
sedimented as wild type, and this protein also had wild-
type adhesion activity (data not shown). However, the
W
 
®
 
F mutation in FN9 gave a protein that was rapidly de-
graded. FN9 has a melting temperature around 50
 
8
 
C,
whereas FN10 melts at 90
 
8
 
C (Litvinovich and Ingham,
1995). We conclude that the less stable FN9 is not able
to fold at room temperature after the W
 
®
 
F mutation,
whereas the more stable FN10 folds normally even with
the mutation. The instability seen for this mutant FN9 is a
typical indication of misfolding, and provides a contrast to
our other mutants, which are properly folded.
 
Discussion
 
One of the more general conclusions of our study is that
the synergy site in FN9 is not limited to the short PHSRN
sequence. The previously identified R1379 in this se-
quence is indeed the most important residue, but the syn-
ergy site receives contributions from several other amino
acids. These are distributed over the surface of FN9, pro-
jecting from the fibronectin surface in the same direction
as the RGD, and presumably making contact with the in-
tegrin. The integrin-binding interface spans at least the 41
Å from R1374 to R1445, and involves several residues be-
tween and beside these residues, forming an extensive in-
tegrin-binding surface. The integrin-binding interface may
extend even farther, as we have not tested more distant
residues.
In contrast to the atomic detail of the FN side of the in-
terface, there is not much information on the structure of
the integrins. Nevertheless, there are several studies that
indicate that the synergy site binds primarily or exclusively
to the 
 
a
 
5 integrin subunit, and that RGD binds to both the
 
a
 
5 and 
 
b
 
1 integrins. We discuss the details of these assign-
ments below. A model showing an integrin in scale with
the FN9-10 atomic model, and indicating the contacts, is
shown in Fig. 7.
The integrin site that binds the synergy region has been
identified primarily from antibody inhibition experiments,
which showed that the synergy- and RGD-binding regions
of 
 
a
 
5
 
b
 
1 are relatively distant (Mould et al., 1998). This is
consistent with the crystal structure of FN7–10 that shows
the R1379 and the RGD are separated by 
 
z
 
32 Å (Leahy
et al., 1996). Antibody data also indicated that the synergy
Figure 5. Competitive inhibition of cell adhesion by soluble pro-
teins. Just before the addition of cells, soluble FN10, FN7–10, or
FN7–10 mutant proteins were added to wells coated with 20 mg/ml
FN7–10, and the plates were subjected to the centrifugation assay.
Figure 6. Gradient sedimentation analysis of FN7–10 mutant
proteins. The indicated proteins were sedimented through 15–
40% glycerol gradients, and the fractions were analyzed by SDS-
PAGE. Ovalbumin (OVA, 3.5 S) and bovine serum albumin
(BSA, 4.6 S) were used as standards. Lanes are labeled as fol-
lows: ST, starting material; 5–10, fractions 5–10; and M, markers
(with size indicated on the lower left gel). The 30–40% recovery
of protein is typical for this type of gradient because of the loss
on the walls of the tubes. 
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site binds to 
 
a
 
5, primarily via the third of its seven NH
 
2
 
-
terminal repeats (Mould et al., 1997; Burrows et al., 1999).
Several studies show that RGD binds to both the
 
 
 
a
 
5
 
 
 
and
 
b
 
1 integrins.
 
 
 
Recombinant fragments of
 
 
 
a
 
5 containing re-
peats IV–VII or III–VII have been shown to bind to RGD
(Banères et al., 1998, 2000). More specifically, these
 
 
 
a
 
5
integrin
 
 
 
fragments have been shown to bind to the RGD
of fibronectin via the carboxylate group of the aspartate,
probably through an intermolecular metal coordination
(Banères et al., 2000).
The case is even stronger for RGD binding the 
 
b
 
 
 
inte-
grin. Cross-linking studies, mutational analysis, and map-
ping of ligand-blocking antibodies show that the
 
 
 
b
 
1 I-like
domain, 
 
z
 
250 amino acids near the NH
 
2
 
 terminus, binds
to RGD (for review see Loftus and Liddington, 1997). Re-
cent studies have refined this observation to show that
 
 
 
b
 
1
binds to the guanidinium of the arginine in the RGD. This
binding is possibly to one of the aspartates in the highly
conserved (among 
 
b
 
 integrin subunits) DDL (Banères et
al., 2000).
Two points of flexibility in FN may be important for its
interaction with the integrin. The solution structures of FN
fragments show that the RGD loop is quite flexible (Main
et al., 1992; Copie et al., 1998), allowing variation in both
its distance from and orientation toward the synergy site.
In addition, the crystal structure of FN7–10 showed that
the interface between FN9 and FN10 is exceptionally
small, suggesting that this junction may be somewhat flexi-
ble (Leahy et al., 1996). NMR solution structures provided
additional evidence that this junction is flexible in solution
 
(Copie et al., 1998). If flexibility at the FN9-10 hinge is im-
portant for adapting FN to different integrins, each inte-
grin may bind FN with a different bend.
The bacterial protein, invasin, binds
 
 
 
a5b1 with 100 times
higher affinity than does FN, and it binds a range of other
b1 integrins. Hamburger et al. (1999) determined the
X-ray structure of invasin and suggested a possible mimic
of FN, including an aspartate residue that might correspond
to the D in RGD, and an arginine and aspartate 32 Å away
that might correspond to R1379 and D1373 in the FN syn-
ergy region. However, the shapes of FN and invasin be-
tween these residues are quite different, FN being concave
and invasin convex. Moreover, invasin is completely rigid.
A pronounced hump of invasin comprising Y863 and Y885
is positioned similarly to the T1385/N1386 of FN, but it
projects much farther. If T1385/N1386 contacts the inte-
grin, as indicated by our data, this same interface could not
accommodate the hump of invasin. Even bending FN at
the FN9-10 hinge cannot bring a match to the convex sur-
face of invasin. An alternative explanation is that invasin
binds to an interface on the integrin that is different from,
but partly overlapping the FN binding site.
Our guiding principle in thinking about the FN–integrin
interface is that protein–protein interfaces are preformed,
rigid, complimentary surfaces that fit together like a lock
and key. This principle was originally proposed by Chothia
and Janin (1975), and has been confirmed by the X-ray
structures of numerous protein–protein complexes. For a
simple protein–protein association the interface is usually
a contiguous patch of amino acids, z20 Å in diameter,
with some hot spots contributing most to the interaction
(Cunningham and Wells, 1993; Clackson and Wells, 1995).
The FN–integrin interaction may well comprise two inter-
faces: one for the synergy site on the a integrin subunit,
and one for RGD in a cleft between the a and b integrins.
The atomic structure of FN has provided important in-
sights into that side of the interface. A complete under-
standing of the interaction must await a comparable
atomic structure of the integrin.
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